Avri Havron
Director/Miembro de la Junta en Active P Ltd. .
Fortuna: 244 174 $ al 31/05/2024
Perfil
Avri Havron is currently a Director at Active P Ltd.
Previously, he worked as a Director at AngioB Ltd.
and as a Principal at Modigen Ltd.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
31/03/2024 | 179 540 ( 0.86% ) | 244 174 $ | 31/05/2024 |
Cargos activos de Avri Havron
Empresas | Cargo | Inicio |
---|---|---|
Active P Ltd.
Active P Ltd. Pharmaceuticals: MajorHealth Technology Active P Ltd. develops proprietary oral available peptide drugs to treat diabetes. The company was founded by Shmulik Hess, Chaim Gilon, and Amnon Hoffman on September 10, 2008 and is headquartered in Kiryat Shmona, Israel. | Director/Miembro de la Junta | 03/03/2010 |
Antiguos cargos conocidos de Avri Havron.
Empresas | Cargo | Fin |
---|---|---|
Modigen Ltd. | Corporate Officer/Principal | - |
AngioB Ltd.
AngioB Ltd. Medical SpecialtiesHealth Technology AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 3 |
---|---|
AngioB Ltd.
AngioB Ltd. Medical SpecialtiesHealth Technology AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel | Health Technology |
Active P Ltd.
Active P Ltd. Pharmaceuticals: MajorHealth Technology Active P Ltd. develops proprietary oral available peptide drugs to treat diabetes. The company was founded by Shmulik Hess, Chaim Gilon, and Amnon Hoffman on September 10, 2008 and is headquartered in Kiryat Shmona, Israel. | Health Technology |
Modigen Ltd. |
- Bolsa de valores
- Insiders
- Avri Havron